+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effect of Nuvastatic on reducing cancer-related fatigue in adults with colon cancer who are undergoing first-line chemotherapy. This Phase III trial compares Nuvastatic to a placebo to determine if it can improve fatigue scores and assess its safety and tolerance in this patient group. The study is designed to provide supportive care alongside standard chemotherapy treatment. Participants will receive either Nuvastatic or placebo sachets, taken three times a day, for three cycles of 20 days each, totaling about 60 days of treatment. Alongside this, they will continue their usual chemotherapy regimen. Blood samples will be collected at screening and at the end of treatment to measure certain biomarkers, including CEA and CA-125. During the study, participants will complete diaries and fatigue assessments as scheduled by the protocol. Researchers will monitor changes in fatigue levels from screening up to 12 weeks and evaluate overall quality of life and functional improvements at the start and end of the study. The trial includes safety monitoring and aims to understand the treatments impact over a 12-week period.

Age: 18Years - 65YearsAll GendersPhase 3
6 locations
P

Actively Recruiting

Researchers are conducting a Phase 1, open-label, dose escalation study to assess the safety, pharmacokinetics PK, and pharmacodynamics PD of an oral drug called AUR112 in patients with relapsed advanced lymphomas. This first-in-human trial aims to find safe and tolerable doses of AUR112 for future studies. The study is led by Aurigene Discovery Technologies Limited and focuses on patients with relapsed or refractory non-Hodgkin lymphoma NHL, chronic lymphocytic leukemia CLL, or Hodgkin disease who have exhausted other effective therapies. Participants will receive AUR112 once daily at increasing dose levels ranging from 100 mg to 1200 mg. The dose escalation follows a classic 33 design, where safety and biological activity data guide dose increases. The study will continue increasing doses until safety limits are reached or biologically active doses are identified. This approach helps determine the most appropriate doses for future clinical trials. During the study, participants will be closely monitored for dose-limiting toxicities and treatment-related adverse events over the first 28 days cycle 1. Researchers will also measure various PK parameters like maximum concentration, time to maximum concentration, and area under the curve on specific days. Assessments include laboratory tests, physical exams, and safety evaluations. The study will help identify doses for further research while ensuring participant safety throughout the trial period.

Age: 18Years - 99YearsAll GendersPhase 1
19 locations